Organogenesis Sees FY21 Revs $456M-$472M Vs $446.28M Est
For the twelve months ended December 31, 2021, the Company now expects:
Net revenue of between $456 million and $472 million, representing an increase of
Organogenesis Holdings Q2 EPS $0.15 Beats $0.07 Estimate, Sales $123.20M Beat $107.30M Estimate
Organogenesis Holdings (NASDAQ:ORGO) reported quarterly earnings of $0.15 per share which beat the analyst consensus estimate of $0.07 by 114.29 percent. This is a 400 percent increase over losses of $(0.05) per share
Earnings Scheduled For August 9, 2021
Companies Reporting Before The Bell
• Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million.
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the week.
Organogenesis Holdings Insights: Return On Capital Employed
Organogenesis Holdings (NASDAQ:ORGO) posted Q1 earnings of $12.62 million, an increase from Q4 of 42.05%. Sales dropped to $102.55 million, a 3.98% decrease between quarters. In Q4, Organogenesis Holdings earned $21.77 million, and total sales reached $106.81 million.
60 Biggest Movers From Yesterday
Gainers
Vertex Energy, Inc. (NASDAQ: VTNR) shares climbed 124.2% to settle at $3.99 on Thursday after the company announced plans to acquire a Alabama refinery and related logistics assets.
Earnings Scheduled For May 10, 2021
Companies Reporting Before The Bell
• Revlon (NYSE:REV) is likely to report earnings for its first quarter.
• Bluegreen Vacations (NYSE:BVH) is expected to report earnings for its first quarter.
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came under pressure following the U.S.